Determinants of Cutaneous Injection-Related Infection Care at a Supervised Injecting Facility

Annals of Epidemiology

Volumn 19, Issue 6, 2009, Pages 404-409

  Lloyd Smith, Elisa ^a   Wood, Evan ^a   Zhang, Ruth ^a   Tyndall, Mark W ^a   Montaner, Julio S ^a   Kerr, Thomas ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Infectious Disease; IV Drug User; Nursing; Statistical Methods

Indexed keywords

ADULT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HEROIN DEPENDENCE; HUMAN; INJECTION SITE INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADULT; COHORT STUDIES; DRUG USERS; FEMALE; HEROIN DEPENDENCE; HOMELESS PERSONS; HUMANS; MALE; NEEDLE-EXCHANGE PROGRAMS; RESIDENCE CHARACTERISTICS; SKIN DISEASES, INFECTIOUS;

EID: 67349261357     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2009.03.007     Document Type: Article

References (34)

1. White A.G. Medical disorders in 200 consecutive admissions. JAMA 223 (1973) 1469-1471
2. Murphy E.L., DeVita D., Liu H., Vittinghoff E., Leung P., Ciccarone D.H., et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis 33 (2001) 35-40
3. Palepu A., Tyndall M.W., Leon H., Muller J., O'Shaughnessy M.V., Schechter M.T., et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ 165 (2001) 415-420
4. del Giudice P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 150 (2004) 1-10
5. Bergstein J.M., Baker E.J., Aprahamian C., Schein M., and Wittmann D.H. Soft tissue abscesses associated with parenteral drug abuse: presentation, microbiology, and treatment. Am Surg 61 (1995) 1105-1108
6. Biller J.A., and Murr A.H. The importance of etiology on the clinical course of neck abscesses. Otolaryngol Head Neck Surg 131 (2004) 338-391
7. Takahashi T.A., Baernstein A., Binswanger I.A., Bradley K., and Merrill J.O. Predictors of hospitalization for injection drug users seeking care for soft tissue infections. J Gen Intern Med 22 (2007) 382-388
8. Harris H.W., and Young D.M. Care of Injection Drug Users With Soft Tissue Infections in San Francisco, California. Arch Surg 137 (2002) 1217-1222
9. Heinzerling K.G., Etzioni D.A., Hurley B., Holtom P., Bluthenthal R.N., and Asch S.M. Hospital Utilization for Injection Drug Use-Related Soft Tissue Infections in Urban versus Rural Counties in California. J Urban Health 83 (2006) 176-181
10. CDC. Soft tissue infections among injection drug users-San Francisco, California, 1996-2000. MMWR Morb Mortal Wkly Rep 50 (2001) 381-384
11. Bluthenthal R.N., Heinzerling K.G., Martinez A., and Kral A. Police crackdowns, societal cost, and the need for alternative approaches. Int J Drug Policy 16 (2005) 137-138
12. Grau L.E., Arevalo S., Catchpool C., and Heimer R. Expanding harm reduction services through a wound and abscess clinic. Am J Public Health 92 (2002) 1915-1917
13. Pollack H.A., Khoshnood K., Blankenship K.M., and Altice F.L. The impact of needle exchange-based health services on emergency department use. J Gen Intern Med 17 (2002) 341-348
14. Wood E., Kerr T., Montaner J.S., Strathdee S.A., Wodak A., Hankins C.A., et al. Rationale for evaluating North America;s first medically supervised safer injecting facility. Lancet Infect Dis 4 (2004) 301-306
15. Kimber J., Dolan K., van Beek I., Hedrich D., and Zurhold H. Drug consumption facilities: an update since 2000. Drug Alcohol Rev 22 (2003) 227-233
16. Lorvick J., Kral A.H., Seal K., Gee L., and Edlin B.R. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 91 (2001) 46-47
17. Dolan K., Kimber J., Fry C., Fitzgerald J., McDonald D., and Frautmann F. Drug Consumption Facilities in Europe and the Establishment of Supervised Injecting Centres in Australia. Drug Alcohol Rev 19 (2000) 337-346
18. Wright N.M., and Tompkins C.N. Supervised injecting centres. BMJ 328 (2004) 100-102
19. Wood E., Kerr T., Lloyd-Smith E., Buchner C., Marsh D.C., Montaner J.S., et al. Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J 1 (2004) 9
20. Kerr T., Tyndall M., Li K., Montaner J.S., and Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 366 (2005) 316-318
21. Wood E., Tyndall M., Li K., Lloyd-Smith E., Small W., Montaner J., et al. Do Supervised Injecting Facilities Attract Higher-Risk Injection Drug Users?. Am J Prev Med 29 (2005) 126-130
22. Wei L., Lin D.Y., and Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 84 (1989) 1065-1073
23. Reid N., and Crepeau H. Influence functions for proportional hazard regression. Biometrika 72 (1985) 1-9
24. Palepu A., Strathdee S.A., Hogg R.S., Anis A.H., Rae S., Cornelisse P.G., et al. The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health 76 (1999) 409-418
25. Spijkerman I.J., van Ameijden E.J., Mientjes G.H., Coutinho R.A., and van den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol 49 (1996) 1149-1154
26. Topp L., Iversen J., Conroy A., Salmon A.M., and Maher L. Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. Aust N Z J Public Health 32 (2008) 34-37
27. Lloyd-Smith E., Kerr T., Hogg R.S., Li K., Montaner J.S., and Wood E. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduct J 2 (2005) 24
28. Shannon K., Kerr T., Bright V., Gibson K., and Tyndall M. Drug sharing with clients as a risk marker for increased violence and sexual and drug-related harms among survival sex workers. AIDS Care 20 (2008) 235-241
29. French M.T., McGeary K.A., Chitwood D.D., and McCoy C.B. Chronic illicit drug use, health services utilization and the cost of medical care. Soc Sci Med 50 (2000) 1703-1713
30. Wood E., Tyndall M.W., Zhang R., Stoltz J.A., Montaner J.S.G., and Kerr T. Attendance at supervised injection facilities and use of detoxification services. N Engl J Med 354 (2006) 2512-2514
31. Wood R.A., Wood E., Lai C., Tyndall M.T., Montaner J.S.G., and Kerr T. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility. Int J Drug Policy 19 (2008) 183-188
32. Wood E., Spittal P.M., Kerr T., Small W., Tyndall M.W., O'Shaughnessy M.V., et al. Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention. Can J Public Health 94 (2003) 355-359
33. O'Connell J.M., Kerr T., Li K., Tyndall M.W., Hogg R.S., Montaner J.S., et al. Requiring help injecting independently predicts incident HIV infection among injection drug users. J Acquir Immune Defic Syndr 40 (2005) 83-88
34. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 51 (1998) 253-263